Manyoo A Agarwal1, Praveen K Potukuchi2, Keiichi Sumida3, Adnan Naseer4, Miklos Z Molnar5, Lekha K George6, Santhosh K Koshy7, Elani Streja8, Fridtjof Thomas9, Kamyar Kalantar-Zadeh8, Csaba P Kovesdy10. 1. Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA; Department of Internal Medicine, Division of Cardiovascular Medicine, University of California Los Angeles, Los Angeles, California, USA. 2. Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 3. Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA; Nephrology Section, Memphis VA Medical Center, Memphis, Tennessee, USA. 4. Methodist University Hospital James D. Eason Transplant Institute, Memphis, Tennessee. 5. Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA; Methodist University Hospital James D. Eason Transplant Institute, Memphis, Tennessee; Division of Transplant Surgery, Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 6. Nephrology Section, Memphis VA Medical Center, Memphis, Tennessee, USA. 7. Division of Cardiovascular Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 8. Harold Simmons Center for Chronic Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California-Irvine, Orange, California, USA. 9. Division of Biostatistics, Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 10. Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA; Nephrology Section, Memphis VA Medical Center, Memphis, Tennessee, USA. Electronic address: ckovesdy@uthsc.edu.
Abstract
OBJECTIVES: The aim of this study was to examine the efficacy and safety of warfarin initiation following the diagnosis of atrial fibrillation (AF) in patients with late-stage chronic kidney disease (CKD) who transitioned to dialysis. BACKGROUND: The clinical benefit of warfarin therapy for thromboprophylaxis after incident AF diagnosis in patients with late-stage CKD who are transitioning to dialysis is unknown. METHODS: In this retrospective cohort analysis, the study population was a national cohort of 22,771 U.S. veterans with incident end-stage renal disease who developed incident AF before initiating renal replacement therapy. This study examined the association of warfarin therapy following the diagnosis of incident AF with ischemic cerebrovascular accidents (CVAs) (ischemic stroke or transient ischemic attack), ischemic CVA-related hospitalization, major bleeding events (gastrointestinal or intracranial bleeding), bleeding event-related hospitalizations, and post-dialysis, all-cause mortality in multivariable adjusted Cox regression analyses that adjusted for demographic characteristics and comorbidities. RESULTS: The mean ± SD age of the cohort was 73.5 ± 8.8 years, 13% were African American, and the mean CHA2DS2-VASc score was 5.7 ± 2.1. Of the overall cohort, 6,682 (29.3%) patients were started on warfarin during the follow-up period. The hazard ratios (95% confidence intervals) for ischemic CVA, bleeding events, and death for those started on warfarin were 1.23 (1.16 to 1.30), 1.36 (1.29 to 1.44), and 0.94 (0.90 to 0.97), respectively, compared with those who received no anticoagulation. Warfarin exposure was associated with higher risk for ischemic CVA and bleeding event-related hospitalizations. CONCLUSIONS: In patients with late-stage CKD who transitioned to dialysis, warfarin use was associated with higher risk of ischemic and bleeding events but a lower risk of mortality. Future studies such as those comparing warfarin with newer oral anticoagulant agents are needed to granularly define the net clinical benefit of anticoagulation therapy in patients with advanced CKD with incident AF. Published by Elsevier Inc.
OBJECTIVES: The aim of this study was to examine the efficacy and safety of warfarin initiation following the diagnosis of atrial fibrillation (AF) in patients with late-stage chronic kidney disease (CKD) who transitioned to dialysis. BACKGROUND: The clinical benefit of warfarin therapy for thromboprophylaxis after incident AF diagnosis in patients with late-stage CKD who are transitioning to dialysis is unknown. METHODS: In this retrospective cohort analysis, the study population was a national cohort of 22,771 U.S. veterans with incident end-stage renal disease who developed incident AF before initiating renal replacement therapy. This study examined the association of warfarin therapy following the diagnosis of incident AF with ischemic cerebrovascular accidents (CVAs) (ischemic stroke or transient ischemic attack), ischemic CVA-related hospitalization, major bleeding events (gastrointestinal or intracranial bleeding), bleeding event-related hospitalizations, and post-dialysis, all-cause mortality in multivariable adjusted Cox regression analyses that adjusted for demographic characteristics and comorbidities. RESULTS: The mean ± SD age of the cohort was 73.5 ± 8.8 years, 13% were African American, and the mean CHA2DS2-VASc score was 5.7 ± 2.1. Of the overall cohort, 6,682 (29.3%) patients were started on warfarin during the follow-up period. The hazard ratios (95% confidence intervals) for ischemic CVA, bleeding events, and death for those started on warfarin were 1.23 (1.16 to 1.30), 1.36 (1.29 to 1.44), and 0.94 (0.90 to 0.97), respectively, compared with those who received no anticoagulation. Warfarin exposure was associated with higher risk for ischemic CVA and bleeding event-related hospitalizations. CONCLUSIONS: In patients with late-stage CKD who transitioned to dialysis, warfarin use was associated with higher risk of ischemic and bleeding events but a lower risk of mortality. Future studies such as those comparing warfarin with newer oral anticoagulant agents are needed to granularly define the net clinical benefit of anticoagulation therapy in patients with advanced CKD with incident AF. Published by Elsevier Inc.
Authors: Charles A Herzog; Richard W Asinger; Alan K Berger; David M Charytan; Javier Díez; Robert G Hart; Kai-Uwe Eckardt; Bertram L Kasiske; Peter A McCullough; Rod S Passman; Stephanie S DeLoach; Patrick H Pun; Eberhard Ritz Journal: Kidney Int Date: 2011-07-13 Impact factor: 10.612
Authors: Konstantinos C Siontis; Xiaosong Zhang; Ashley Eckard; Nicole Bhave; Douglas E Schaubel; Kevin He; Anca Tilea; Austin G Stack; Rajesh Balkrishnan; Xiaoxi Yao; Peter A Noseworthy; Nilay D Shah; Rajiv Saran; Brahmajee K Nallamothu Journal: Circulation Date: 2018-10-09 Impact factor: 29.690
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: Rajiv Saran; Bruce Robinson; Kevin C Abbott; Jennifer Bragg-Gresham; Xiaoying Chen; Debbie Gipson; Haoyu Gu; Richard A Hirth; David Hutton; Yan Jin; Alissa Kapke; Vivian Kurtz; Yiting Li; Keith McCullough; Zubin Modi; Hal Morgenstern; Purna Mukhopadhyay; Jeffrey Pearson; Ronald Pisoni; Kaitlyn Repeck; Douglas E Schaubel; Ruth Shamraj; Diane Steffick; Megan Turf; Kenneth J Woodside; Jie Xiang; Maggie Yin; Xiaosong Zhang; Vahakn Shahinian Journal: Am J Kidney Dis Date: 2019-11-05 Impact factor: 8.860
Authors: Vaibhav Keskar; Eric McArthur; Ron Wald; Ziv Harel; Deborah Zimmerman; Amber O Molnar; Amit X Garg; Ngan N Lam; Megan K McCallum; Sarah E Bota; Jeffrey Perl; Manish M Sood Journal: Kidney Int Date: 2016-12-22 Impact factor: 10.612
Authors: Volker Wizemann; Lin Tong; Sudtida Satayathum; Alex Disney; Takashi Akiba; Rachel B Fissell; Peter G Kerr; Eric W Young; Bruce M Robinson Journal: Kidney Int Date: 2010-01-06 Impact factor: 10.612
Authors: Josep Redon; Maria Jose Forner; Jose Miguel Calderon; Fernando Martinez; Antonio Fernandez; Inmaculada Sauri; Javier Diaz; Ruth Uso; Jose Luis Trillo Journal: Sci Rep Date: 2022-04-12 Impact factor: 4.379